Acrux (ASX:ACR)
ASX announcement history & article coverage
Transparent by design.
Announcments by Acrux (ASX:ACR) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Notice of Annual General Meeting/Proxy Form
Application for quotation of securities - ACR
Quarterly Activities/Appendix 4C Cash Flow Report
Acrux receives FDA Phase III clarity for female testosterone spray and reports positive quarterly operating cash flow
FDA clears regulatory pathway for Female Testosterone MDTS
FDA confirms Phase III pathway and potential three-year exclusivity for Acrux female testosterone spray
Webinar, Monday 12 October 2026 - Female Testosterone MDTS
Acrux to provide investor update on Female Testosterone MDTS and FDA feedback
Acrux has received $1.977m RDTI rebate for FY26
Acrux receives $1.977 million FY26 R&D rebate and retains $905,000 net
Application for quotation of securities - ACR
AGM date, closing date for director nominations
Appendix 3Y Brooke
Application for quotation of securities - ACR
Appendix 3Y Brooke
Appendix 3Y Warmbrunn
Appendix 3Y Oldham
Appendix 3Y Brumley
Appendix 3Y Dobinson
Application for quotation of securities - ACR
Application for quotation of securities - ACR
FY26 Appendix 4G and Corporate Governance Statement
FY26 Annual Report and Appendix 4E
Acrux FY26 revenue up 46%, net loss narrows 90%, advances Female Testosterone MDTS development
Acrux appoints Chief Medical Officer
Webinar invitation for 17 August 2026, 11am
Application for quotation of securities - ACR
Notification of cessation of securities - ACR
Investor Presentation - Female Testosterone for HSDD
Acrux presents Female Testosterone MDTS development and market opportunity at Bioshares Biotech Summit
Quarterly Activities/Appendix 4C Cash Flow Report
Acrux reports strong revenue growth, FDA Phase III pathway for Female Testosterone, and $1.6M funding
Cleansing Notice
Application for quotation of securities - ACR
Notification regarding unquoted securities - ACR